MLYS — Mineralys Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1933414 ·
Last close
$25.52
Market Cap
$2.25B
52W High
$32.14
52W Low
$22.30
ADV30
1,190,680
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -45,340,000 | -39,339,000 | 652,862,000 | 112,779,000 | 14,718,000 |
| Dec 2025 | 0 | — | -38,280,000 | -32,234,000 | 661,806,000 | 172,921,000 | 15,113,000 |
| Sep 2025 | 0 | — | -41,131,000 | -36,932,000 | 599,947,000 | 217,597,000 | 23,520,000 |
| Jun 2025 | 0 | — | -46,746,000 | -43,274,000 | 335,724,000 | 101,788,000 | 22,173,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-142,416,000
Investing CF
$-389,753,000
Financing CF
$590,999,000
CapEx
$-37,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.37
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-457,169,000
Inventory
—
Receivables
—
ST Investments
$483,714,000
EBIT TTM
$-170,604,000
Pretax Income TTM
$-154,651,000
Interest Exp TTM
—
Analysts
8
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -170,604,000 | -154,651,000 | 661,806,000 | 15,113,000 | — | -142,416,000 |
| Dec 2024 | 0 | -192,403,000 | -177,810,000 | 205,903,000 | 14,646,000 | — | -166,314,000 |
| Dec 2023 | 0 | -84,657,000 | -71,898,000 | 251,636,000 | 10,482,000 | — | -81,173,000 |
| Dec 2022 | 0 | -31,479,000 | -29,799,000 | 114,442,000 | 166,711,000 | — | -29,221,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-85,780,000
OpCashFlow TTM
$0
Assets (Latest)
$205,903,000
Forward EPS
$-2.10
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AMLX | Amylyx Pharmaceuticals, Inc. | $2.26B | $20.31 | — |
| PGEN | PRECIGEN, INC. | $2.24B | $6.27 | — |
| PHVS | Pharvaris N.V. | $2.28B | $32.62 | — |
| GIFOF | Grifols SA | $2.29B | $8.85 | — |
| NUVB | Nuvation Bio Inc. | $2.20B | $6.33 | — |
News headlines (Yahoo Finance, 1h cache)
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2026-07-27 20:01 · Yahoo
A Mineralys Insider Banked a $557,000 Options Gain Before a December FDA Date
2026-07-16 21:05 · Yahoo
What to Know About This Mineralys Insider Sale Before a December FDA Date
2026-07-16 20:57 · Yahoo
A $500 Million Funding Deal Could Make Mineralys Therapeutics (MLYS) Stock A Multibagger
2026-07-03 13:41 · Yahoo
Is Mineralys Therapeutics, Inc. (MLYS) Stock a Biotech Opportunity With Lorundrostat’s Expanding Cardiovascular Potential?
2026-07-02 19:58 · Yahoo
What a $350,000 Insider Sale Might Mean for Mineralys Ahead of December FDA Decision
2026-06-23 21:39 · Yahoo
Mineralys Therapeutics (MLYS) Prices $150M Public Offering of Common Stock
2026-06-17 18:29 · Yahoo
Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)
2026-06-14 14:00 · Yahoo
Mineralys Therapeutics (MLYS) to Repurchase Potential Royalties for Lorundrostat
2026-06-11 10:20 · Yahoo
Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
2026-06-08 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.